Program Description
As a complex, chronic disease, obesity requires lifelong management. Because weight regain and metabolic complications frequently follow treatment discontinuation, ongoing strategies are essential to support long-term patient success. This webinar highlights approaches for pharmacists to address the pathophysiology and clinical burden of obesity. Faculty will synthesize key concepts from “The Educated Pharmacist—Weighing In” curriculum, guiding participants to apply current guidelines and clinical evidence when selecting appropriate candidates for glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist therapy based on obesity severity, cardiorenal-metabolic comorbidities, and patient-specific factors. Learners will explore how to develop individualized treatment plans incorporating precise medication selection, dose titration, administration techniques, adverse effect management, and nonpharmacologic interventions. The discussion will explore practical methods to overcome patient-, provider-, and system-level barriers to long-term obesity therapy persistence. Through a faculty-led patient case discussion, participants will examine real-world approaches to implement pharmacist-led strategies that enhance treatment initiation, persistence, and adherence through patient-centered counseling, motivational interviewing, and structured follow-up.
Target audience: Community Pharmacists
Type of activity: Application
Release date:
October 2, 2026
Expiration date: December 2, 2026
Time to complete activity: 1.5 hours
Learner level: Intermediate
Fee: Free
Educational Objectives
After completion of this activity, participants will be able to:
- Explain the pathophysiology and clinical burden of obesity and the impact of clinical inertia on the initiation and optimization of evidence-based treatment
- Apply current guidelines and clinical evidence to identify appropriate candidates for GLP-1 receptor agonist and dual GIP/GLP-1 receptor agonist therapy based on obesity severity, cardiorenal-metabolic comorbidities, expected benefits, safety considerations, and patient-specific factors
- Explore individualized treatment plans that incorporate medication selection, dose titration, administration technique, adverse effect mitigation and management, and nonpharmacologic interventions
- Identify pharmacist-led strategies to address barriers to treatment initiation, persistence, and long-term adherence through patient-centered counseling, motivational interviewing, and follow-up
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-284-L01-P. The activity is available for CE credit through December 2, 2026.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Disclosures
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, has the following relevant financial relationships with ineligible companies to disclose:
Speakers Bureau: Abbott Diabetes, Amgen, CeQur, Lilly, Novo Nordisk, Xeris
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Emily Tyler; and Brianna Winters have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not
constitute any form of professional advice or referral. Discussions concerning
drugs, dosages, and procedures may reflect the clinical experience of the
author(s) or they may be derived from the professional literature or other
sources and may suggest uses that are investigational in nature and not
approved labeling or indications. Participants are encouraged to refer to primary
references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms